The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Definitely an increase in interest today and a number of Buys coming in. Small steps but encouraging.
and a slight pick up in trades - all Buys. :-)
pablo and prince09.... Now, a huge 1.6m BUY has gone through today. I also notice that there were two large SELLS back on the 31st May which equal virtually the same number of shares. Were they the opposite side of this trade? Will this make any difference now? Probably not unless we start to get some volume, we need volume!
This will boom, the value of this company is clearly not incorporated in the share price.....and hopefully when it does go up ill be there to see it!
Nothing, there's nothing I don't like. Great company, just wish the sp would respond. I've thought for a couple of years this would be bought out at some stage, but they've resisted so far. Nice statement today : 'year to date revenue has increased by over 35% compared with the same period last year.'
Source BioScience is indeed a rare beast on AIM. A company that makes profits! Low borrowing. Cash in the bank. Good management. A very promising outlook. Close ties to the NHS through its cervical cancer screening programme and in the very important healthcare and life sciences space. What's not to like? A company that has a MC of just £20m. I see dozens of AIM companies with market valuations way in excess of this that are not a patch on this company in terms of the observations made above. Amazing. My conclusion is that currently this share is simply not in vogue, perhaps it's just overlooked. Over time though this WILL change and the market WILL wake up to this, a rare quality proposition on the AIM. Good solid statement today in advance of the AGM. I expect to see this make progress in the 2nd half of this year.
For the first time in maybe two weeks. As pablo says a good solid share by AIM standards but with no little upside potential. Can see big growth here looking at the long term story. Thats what I'm here for and I do feel this WILL start to get noticed by the market as time goes by.
Cash position solid; acquisition paid for with cash; trading as expected; generally performing well. I've been holding a couple of years or so now and there don't seem to be many fireworks or bombshells with this company. Was hoping it's medical specialities would take off OR be taken over. Meanwhile it plods along unaware of financial crises, pog, or any other pitfalls. No divi and no take-off or takeover au moment. Could do with an analyst upgrade or something to get it noticed/moving.
yes they continue ,there great record over the last few years ,shame the price dont reflect the good work the bod are doing
Encouraging update from the company. Looking good for further growth this year.
shan - SBS has been on my watchlist for sometime now. Had some funds freed up and this looked like a reasonable entry point but this is definitely a long term investment. No way can you trade this share. I believe if you are placing yourself in the medical diagnostics AND DNA technology space you are putting yourself in the right place at the right time. But not too much buying yet please I want to load up first. Ta.
I had an interview for SBS once in Nottingham. Didn't get the job but very nice company and people - I recall they were expanding one of their labs too so defo good long term investment imho..not invested myself but on watchlist.
great company ,one day the rewards will be very ,well run company and do a great job for nhs etc
I've taken a small initial position in here today. Done my research. This is a darn good company. Clearly underrated and tons of potential. Good recent acquisition with no dilution - nice. See this as an excellent long term INVESTMENT. If I get more spare funds I'll add further.
I've been watching this company for a while. Good to see they've got the turnover, got the profit, got the cash flow and only valued at 22 times last years pre tax profit. What's not to like.
I have just read their RNS - good results,seems like its still out of the radar though.
Great results - if these results aren't already predicted, this is going to get quite a boost today.
3 weeks to finals ,hopefully give it a good boost
York has also committed to implementing Source BioScience's automated cervical cancer screening BD FocalPoint™ technology. The agreement is worth a total of £1.3 million over three years and will commence on 1 April 2013. More contracts with NHS Trusts likely to follow. Excellent company, ground-breaking technology, small market cap of £22m and only 66% free float of shares. What'snot to like?
Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations. The company said the three months to the end of September had been a period of sustained growth and development with increased revenue in both its LifeSciences and Healthcare divisions. The performance was underpinned by growth in the firm's cytology business (which studies cell structure), driven by the adoption of automated imaging for cervical cancer screening. The LifeSciences division also took increasing market share for DNA sequencing in the UK. Source said it was in a robust financial position with £2m cash as of September 30th, up from £1.8m at the end of June.
seriously underated company ,proven track record for a few years ,strong buy
Healthcare division Demand for our liquid based cytology (`LBC') service, which supports 50% of the Cervical Cancer Screening Programme for England and Wales, continues to be strong. The roll out of the BD FocalPoint™ automated imaging platform for cervical cancer screening has driven growth in the Cytology business. In the short term, we expect a number of additional NHS Trusts to adopt this imaging technology. Molecular diagnostic testing continues to gain clinical relevance and importance in the NHS, especially gene-based companion diagnostic testing. Companion diagnostic testing provides information about how a patient might respond to a particular drug therapy. One of the most widely utilised tests is the K-RAS gene test for colorectal cancer and demand in the period was up more than 70% compared with the same period last year. Source BioScience is one of only a few accredited laboratories in Europe with the capability to deliver this type of complex diagnostic testing and the growing demand strengthens the Group's commercial advantage. To conclude, the Group has made good progress in the period and we expect full year profits to be in line with market expectations.